The risk or severity of adverse effects can be increased when Metamizole is combined with Fludrocortisone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Ponatinib. Metamizole may increase the nephrotoxic activities of Tacrolimus. The risk or severity of adverse effects can be increased when Metamizole is combined with Etidronic acid. The risk or severity of adverse effects can be increased when Salicylic acid is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Flurandrenolide. The risk or severity of adverse effects can be increased when Castanospermine is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Estrone sulfate. The risk or severity of adverse effects can be increased when Tenoxicam is combined with Metamizole. Metamizole may increase the anticoagulant activities of Antithrombin III human. The risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol. The risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant. The risk or severity of adverse effects can be increased when Forasartan is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with SRT501. The risk or severity of myelosuppression can be increased when Metamizole is combined with Eribulin. Metamizole may decrease the antihypertensive activities of Labetalol. The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Ibuprofen is combined with Metamizole. The risk or severity of adverse effects can be increased when Meloxicam is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Oxprenolol. Metamizole may decrease the excretion rate of Amrubicin which could result in a higher serum level. The risk or severity of myelosuppression can be increased when Metamizole is combined with Doxorubicin. Metamizole may decrease the antihypertensive activities of Talinolol. The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Capecitabine. Metamizole may increase the anticoagulant activities of Gabexate. Sarilumab may increase the immunosuppressive activities of Metamizole. The risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole. The risk or severity of myelosuppression can be increased when Metamizole is combined with Dacarbazine. The risk or severity of adverse effects can be increased when Metamizole is combined with Anisodamine. The risk or severity of adverse effects can be increased when Metamizole is combined with Tiludronic acid. The risk or severity of adverse effects can be increased when Metamizole is combined with Androstenedione. Metamizole may decrease the antihypertensive activities of Eplerenone. The risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole. Metamizole may decrease the excretion rate of Plazomicin which could result in a higher serum level. Cholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of myelosuppression can be increased when Metamizole is combined with Methimazole. The risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol. The risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole. Metamizole may increase the neuroexcitatory activities of Pazufloxacin. The risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone. The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Equilin. The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-n3. The risk or severity of adverse effects can be increased when Captopril is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Bisoprolol. The risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Carvedilol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Idarubicin. The serum concentration of Pralatrexate can be increased when it is combined with Metamizole. The therapeutic efficacy of Beraprost can be decreased when used in combination with Metamizole. Metamizole may increase the anticoagulant activities of Reviparin. The risk or severity of myelosuppression can be increased when Metamizole is combined with Lomustine. Metamizole may decrease the antihypertensive activities of Celiprolol. Metamizole may increase the anticoagulant activities of Protocatechualdehyde. The risk or severity of myelosuppression can be increased when Metamizole is combined with Aldesleukin. Metamizole may increase the anticoagulant activities of Nafamostat. The risk or severity of myelosuppression can be increased when Metamizole is combined with Daunorubicin. Metamizole may increase the neuroexcitatory activities of Enoxacin. The risk or severity of myelosuppression can be increased when Metamizole is combined with Streptozocin. The risk or severity of adverse effects can be increased when Metamizole is combined with Tinoridine. The therapeutic efficacy of Folic Acid can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Ciclesonide. The therapeutic efficacy of Sulprostone can be decreased when used in combination with Metamizole. The therapeutic efficacy of Limaprost can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Methotrexate is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Bufuralol. Metamizole may increase the neuroexcitatory activities of Fleroxacin. The risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate. Metamizole may decrease the antihypertensive activities of Practolol. The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole. Metamizole may decrease the excretion rate of Geneticin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with Zoledronic acid. The risk or severity of myelosuppression can be increased when Metamizole is combined with Oxaliplatin. Metamizole may increase the anticoagulant activities of Warfarin. The risk or severity of myelosuppression can be increased when Metamizole is combined with Topotecan. The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Loxoprofen. The risk or severity of myelosuppression can be increased when Metamizole is combined with Vinblastine. The therapeutic efficacy of Tafluprost can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Parecoxib. Metamizole may decrease the antihypertensive activities of Arotinolol. The risk or severity of myelosuppression can be increased when Metamizole is combined with Ibrutinib. The therapeutic efficacy of Polythiazide can be decreased when used in combination with Metamizole. The risk or severity of adverse effects can be increased when Zofenopril is combined with Metamizole. Metamizole may increase the anticoagulant activities of Apixaban. The risk or severity of myelosuppression can be increased when Metamizole is combined with Docetaxel. The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Metamizole. The risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole. Metamizole may decrease the excretion rate of Kanamycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with Paramethasone. Metamizole may increase the anticoagulant activities of Pentosan Polysulfate. Metamizole may increase the nephrotoxic activities of Olsalazine. Metamizole may decrease the antihypertensive activities of Nebivolol. Metamizole may decrease the antihypertensive activities of Bevantolol. The risk or severity of adverse effects can be increased when Metamizole is combined with Evening primrose oil. The risk or severity of myelosuppression can be increased when Metamizole is combined with Obinutuzumab. The risk or severity of adverse effects can be increased when Ketorolac is combined with Metamizole. Metamizole may increase the anticoagulant activities of Ethyl biscoumacetate. The risk or severity of myelosuppression can be increased when Metamizole is combined with Busulfan. The risk or severity of adverse effects can be increased when Metamizole is combined with Nitroaspirin. The serum concentration of Rilpivirine can be decreased when it is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Etofenamate. The serum concentration of Saxagliptin can be decreased when it is combined with Metamizole. Metamizole may decrease the antihypertensive activities of Levobunolol. Metamizole may decrease the excretion rate of Gentamicin which could result in a higher serum level. The risk or severity of myelosuppression can be increased when Metamizole is combined with Gemtuzumab ozogamicin. The risk or severity of adverse effects can be increased when Metamizole is combined with Serrapeptase. Metamizole may decrease the antihypertensive activities of Timolol. The risk or severity of adverse effects can be increased when Metamizole is combined with Cortisone acetate. Metamizole may increase the anticoagulant activities of Protein S human. The risk or severity of myelosuppression can be increased when Metamizole is combined with Trabectedin. The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Metamizole. The risk or severity of adverse effects can be increased when Metamizole is combined with Clodronic Acid. Metamizole may increase the anticoagulant activities of Edetic Acid. Metamizole may decrease the excretion rate of Puromycin which could result in a higher serum level. Metamizole may increase the anticoagulant activities of Edoxaban. The risk or severity of adverse effects can be increased when Metamizole is combined with Oleoyl-estrone. The risk or severity of myelosuppression can be increased when Metamizole is combined with Dinutuximab. Metamizole may increase the anticoagulant activities of Pentaerythritol Tetranitrate. The risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone. The risk or severity of adverse effects can be increased when Metamizole is combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole. Metamizole may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with HE3286. The risk or severity of adverse effects can be increased when Quinapril is combined with Metamizole. Metamizole may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. The risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid. The risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.